Early Blood Test Predicts Long-Term Multiple Sclerosis Outcomes
Levels of proteins in the cerebrospinal fluid (CSF) can help predict disease activity and disability worsening in people with multiple sclerosis (MS). Researchers in Sweden analyzed protein levels in the CSF and plasma of MS patients and found several promising biomarkers that could predict short-term activity and long-term disease progression. These findings could aid in the development of personalized treatment protocols for MS patients, helping to avoid over- or under-treatment and improve outcomes.